Point-of-care device manufacturer Abaxis and biosensor firm LamdaGen said this week that they have entered into an R&D agreement aiming to integrate LamdaGen's plasmonic ELISA technology on Abaxis's rotor-based POC platforms.
If the integration proves viable, the agreement would enable Abaxis to multiplex a variety of markers on its rotor-based system, Abaxis CEO Clint Severson said in a statement.
"Both medical and veterinary customers will be able to simultaneously analyze for chemistry parameters as well as for infectious disease, hormones and a wide range of other markers on the same rotor," he said. "The ability to unify both diagnostic systems
onto our existing rotor will greatly expand Abaxis’ global diagnostic offerings.”
LamdaGen's biosensor platform is based on localized surface plasmon resonance, offering quantitative results and detection levels in the femtomolar range.
Financial and other terms of the agreement were not disclosed.